Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Chen

Plastic Surgery Richmond, VA Medical Doctor

NPI 1245313311 CMS profile 328284

1630 Wilkes Ridge Pkwy Ste 201, Richmond, VA 23233

Open in the dashboard

General payments

$8,562

123 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephen Chen of Richmond, VA is reported in the CMS Open Payments database as having received $8,562 across 123 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $465 13
2024 General $1,277 28
2023 General $968 14
2022 General $772 13
2021 General $1,393 18
2020 General $1,371 15
2019 General $2,315 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Chen
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Stephen Chen were reported at $465. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Stephen Chen Plastic Surgery median Middle half National median
2019 $2,315 $371 $122–$1,483 $163
2020 $1,371 $158 $52–$438 $114
2021 $1,393 $249 $87–$752 $132
2022 $772 $274 $102–$793 $149
2023 $968 $299 $113–$891 $160
2024 $1,277 $361 $124–$1,062 $164
2025 $465 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sientra, Inc. $1,962 20 payments
  2. Davol Inc. $1,234 12 payments
  3. Allergan Inc. $1,194 13 payments
  4. Mentor Worldwide LLC $1,149 25 payments
  5. Musculoskeletal Transplant Foundation Inc. $785 6 payments
  6. Revance Therapeutics, Inc. $340 13 payments
  7. Tepha Inc $281 6 payments
  8. Apyx Medical Corporation $251 2 payments
  9. Motiva USA, LLC $227 6 payments
  10. E.R. Squibb & Sons, L.L.C. $203 2 payments
  11. Other $935 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,157 121 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $370 1 payment
  3. Consulting Fee $35 1 payment
Products named General payments · program years 2019–2025
  1. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $1,962 20 payments
  2. MENTOR MemoryGel Resterilizable Gel Sizer $868 22 payments
  3. Phasix Mesh $620 5 payments
  4. NATRELLE $511 7 payments
  5. ARISTA AH FlexiTip $448 3 payments
  6. ARTOURA Breast Tissue Expander $406 5 payments
  7. DAXXIFY $340 13 payments
  8. MemoryGel Breast Implants $281 3 payments
  9. GalaFLEX $281 6 payments
  10. Motiva Implant Matrix $227 6 payments
  11. Other $1,448 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

27

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$172

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

100%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 16 $102
Ondansetron Odt Ondansetron Brand 11 $71

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$19,310

Medicare's payments for the services billed

Medicare patients

49

Average age 73

Services billed

112

36 women, 13 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 39%
Cancer 29%
Chronic kidney disease 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $137
$137 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record